Assessment of secondary cancer risks within non-target organs during proton therapy for lung cancer: A Monte Carlo study

IF 1.6 3区工程技术 Q3 CHEMISTRY, INORGANIC & NUCLEAR

Applied Radiation and Isotopes Pub Date : 2024-09-25 DOI:10.1016/j.apradiso.2024.111532

Sayyed Bijan Jia , Reza Shamsabadi , Leili Mogheiseh , Hamid Reza Baghani

{"title":"Assessment of secondary cancer risks within non-target organs during proton therapy for lung cancer: A Monte Carlo study","authors":"Sayyed Bijan Jia , Reza Shamsabadi , Leili Mogheiseh , Hamid Reza Baghani","doi":"10.1016/j.apradiso.2024.111532","DOIUrl":null,"url":null,"abstract":"<div><div>Proton therapy is a rapidly progressing modality with a significant impact on lung cancer treatment. However, there are concerns about the subsequent effects of secondary radiation in out-of-field organs. Thus, the present study aimed to evaluate the risk of subsequent secondary cancers within non-target organs during proton therapy for lung cancer. A Monte Carlo model of the International Commission on Radiological Protection (ICRP) 110 male phantom was employed to calculate the absorbed dose associated with secondary photons and neutrons within out-of-field organs for different tumor locations. The risk of induced secondary cancers was then estimated using the Biological Effects of Ionizing Radiation Committee (BEIR) VII and National Council on Radiation Protection and Measurements (NCRP) 116 risk models. Organs close to the tumor, such as the heart, esophagus, thymus, and liver, received the highest equivalent doses. The calculated equivalent doses increased as the tumor depth increased from 4–8 cm to 12–16 cm. The contribution of neutrons to the total equivalent dose was dominant (up to 90%) in most of the organs studied. The calculated risks of secondary cancers were higher in the liver and esophagus compared with other organs when using the BEIR risk model. The maximum risk value was obtained for the left lung when the NCRP 116 risk model was used. Furthermore, the estimated risks of secondary malignancies increased with the tumor depth using both risk models. The calculated risks of radiation-induced secondary cancers were relatively lower than the baseline cancer risks. However, extra attention is warranted to minimize subsequent secondary cancers after proton therapy for lung cancer.</div></div>","PeriodicalId":8096,"journal":{"name":"Applied Radiation and Isotopes","volume":"214 ","pages":"Article 111532"},"PeriodicalIF":1.6000,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Applied Radiation and Isotopes","FirstCategoryId":"5","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0969804324003609","RegionNum":3,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, INORGANIC & NUCLEAR","Score":null,"Total":0}

引用次数: 0

Abstract

Proton therapy is a rapidly progressing modality with a significant impact on lung cancer treatment. However, there are concerns about the subsequent effects of secondary radiation in out-of-field organs. Thus, the present study aimed to evaluate the risk of subsequent secondary cancers within non-target organs during proton therapy for lung cancer. A Monte Carlo model of the International Commission on Radiological Protection (ICRP) 110 male phantom was employed to calculate the absorbed dose associated with secondary photons and neutrons within out-of-field organs for different tumor locations. The risk of induced secondary cancers was then estimated using the Biological Effects of Ionizing Radiation Committee (BEIR) VII and National Council on Radiation Protection and Measurements (NCRP) 116 risk models. Organs close to the tumor, such as the heart, esophagus, thymus, and liver, received the highest equivalent doses. The calculated equivalent doses increased as the tumor depth increased from 4–8 cm to 12–16 cm. The contribution of neutrons to the total equivalent dose was dominant (up to 90%) in most of the organs studied. The calculated risks of secondary cancers were higher in the liver and esophagus compared with other organs when using the BEIR risk model. The maximum risk value was obtained for the left lung when the NCRP 116 risk model was used. Furthermore, the estimated risks of secondary malignancies increased with the tumor depth using both risk models. The calculated risks of radiation-induced secondary cancers were relatively lower than the baseline cancer risks. However, extra attention is warranted to minimize subsequent secondary cancers after proton therapy for lung cancer.

查看原文本刊更多论文

评估质子治疗肺癌期间非靶器官内的继发性癌症风险：蒙特卡洛研究

质子疗法是一种进展迅速的治疗方式，对肺癌治疗具有重大影响。然而，人们对场外器官二次辐射的后续影响表示担忧。因此，本研究旨在评估质子治疗肺癌期间非靶器官发生二次癌症的风险。研究采用了国际放射防护委员会（ICRP）110 男性模型的蒙特卡洛模型，计算不同肿瘤位置场外器官内与二次光子和中子相关的吸收剂量。然后使用电离辐射生物效应委员会（BEIR）VII 和国家辐射防护和测量委员会（NCRP）116 风险模型估算诱发继发性癌症的风险。靠近肿瘤的器官，如心脏、食道、胸腺和肝脏，受到的当量剂量最高。随着肿瘤深度从 4-8 厘米增加到 12-16 厘米，计算出的当量剂量也随之增加。在所研究的大多数器官中，中子对总当量剂量的贡献占主导地位（高达 90%）。与其他器官相比，使用 BEIR 风险模型计算出的肝脏和食道患继发性癌症的风险更高。使用 NCRP 116 风险模型时，左肺的风险值最高。此外，使用这两种风险模型，继发性恶性肿瘤的估计风险随着肿瘤深度的增加而增加。计算得出的辐射诱发继发性癌症的风险相对低于基线癌症风险。不过，在质子治疗肺癌后，应格外注意尽量减少继发性癌症的发生。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Applied Radiation and Isotopes 工程技术-核科学技术

CiteScore

3.00

自引率

12.50%

发文量

406

审稿时长

13.5 months

期刊介绍： Applied Radiation and Isotopes provides a high quality medium for the publication of substantial, original and scientific and technological papers on the development and peaceful application of nuclear, radiation and radionuclide techniques in chemistry, physics, biochemistry, biology, medicine, security, engineering and in the earth, planetary and environmental sciences, all including dosimetry. Nuclear techniques are defined in the broadest sense and both experimental and theoretical papers are welcome. They include the development and use of α- and β-particles, X-rays and γ-rays, neutrons and other nuclear particles and radiations from all sources, including radionuclides, synchrotron sources, cyclotrons and reactors and from the natural environment. The journal aims to publish papers with significance to an international audience, containing substantial novelty and scientific impact. The Editors reserve the rights to reject, with or without external review, papers that do not meet these criteria. Papers dealing with radiation processing, i.e., where radiation is used to bring about a biological, chemical or physical change in a material, should be directed to our sister journal Radiation Physics and Chemistry.